口服抗病毒治疗启动时HBeAg状态对慢性乙型肝炎患者肝癌风险的影响
本研究在韩国慢性乙型肝炎队列中评估启动恩替卡韦或替诺福韦时HBeAg状态与肝细胞癌(HCC)风险的关系,并在高加索PAGE-B队列中验证。韩国队列共9143例,中位随访5.1年,916例(10.0%)发生HCC;HBeAg阳性在非肝硬化亚组中与较低HCC风险独立相关,在肝硬化亚组无此关联。
要点
- 非肝硬化慢性乙肝患者启动抗病毒治疗时HBeAg阳性与较低HCC风险独立相关。
- 肝硬化亚组中HBeAg状态与HCC风险无显著关联。
- 高加索验证队列非肝硬化亚组HBeAg阳性者无HCC发生,但差异未达统计学显著。
核心结论
- 在无肝硬化的慢性乙型肝炎患者中,启动口服抗病毒治疗时HBeAg阳性似乎是HCC风险较低的独立因素,但在肝硬化患者中无此关联。
研究设计与样本
- 多国队列研究,韩国队列纳入9143例启动恩替卡韦或替诺福韦的慢性乙型肝炎患者(平均年龄49.2岁),并在高加索PAGE-B队列(n=719)中验证。
主要发现
- 韩国队列中位随访5.1年,916例(10.0%)发生HCC;整个队列及肝硬化亚组中基线HBeAg阳性与HCC风险无关。
- 韩国非肝硬化亚组中,HBeAg阳性在多变量分析(aHR 0.41,95%CI 0.26-0.66)、倾向评分匹配(aHR 0.46,95%CI 0.28-0.76)和逆概率加权分析(aHR 0.44,95%CI 0.28-0.70)中均与较低HCC风险独立相关。
- 高加索队列(平均年龄51.8岁,HBeAg阳性20.3%,肝硬化34.8%)中,整个队列及肝硬化亚组HBeAg阳性与HCC风险无关;非肝硬化亚组HBeAg阳性组无HCC发生,但差异未达统计学显著(aHR 0.21,95%CI 0.00-1.67)。
临床怎么用
- 对于无肝硬化的慢性乙型肝炎患者,启动抗病毒治疗时HBeAg阳性可提示HCC风险相对较低,但仍需按指南进行HCC监测。
- 肝硬化患者无论HBeAg状态如何,均应视为HCC高风险人群并坚持监测。
局限性
- 高加索验证队列非肝硬化亚组中HBeAg阳性者无HCC发生,但差异未达统计学显著,需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Antiviral treatment from hepatitis B envelope antigen (HBeAg)-positive status may attenuate the integration of hepatitis B virus DNA into the host genome causing hepatocellular carcinoma (HCC). We investigated the impact of HBeAg status at the onset of antiviral treatment on the risk of HCC. METHODS: The incidence of HCC was evaluated in Korean patients with chronic hepatitis B who started entecavir or tenofovir in either HBeAg-positive or HBeAg-negative phase. The results in the Korean cohort were validated in a Caucasian PAGE-B cohort. RESULTS: A total of 9143 Korean patients (mean age, 49.2 years) were included: 49.1% were HBeAg-positive and 49.2% had cirrhosis. During follow-up (median, 5.1 years), 916 patients (10.0%) developed HCC. Baseline HBeAg positivity was not associated with the risk of HCC in the entire cohort or cirrhotic subcohort. However, in the non-cirrhotic subcohort, HBeAg positivity was independently associated with a lower risk of HCC in multivariable (adjusted hazard ratio [aHR], 0.41; 95% confidence interval [CI], 0.26-0.66), propensity score-matching (aHR, 0.46; 95% CI, 0.28-0.76), and inverse probability weighting analyses (aHR, 0.44; 95% CI, 0.28-0.70). In the Caucasian cohort (n = 719; mean age, 51.8 years; HBeAg-positive, 20.3%; cirrhosis, 34.8%), HBeAg-positivity was not associated with the risk of HCC either in the entire cohort or cirrhotic subcohort. In the non-cirrhotic subcohort, none of the HBeAg-positive group developed HCC, although the difference failed to reach statistical significance (aHR, 0.21; 95% CI, 0.00-1.67). CONCLUSIONS: This multinational cohort study implies that HBeAg positivity at the onset of antiviral treatment seems to be an independent factor associated with a lower risk of HCC in patients with chronic hepatitis B without cirrhosis, but not in those with cirrhosis.
引用
- Jang H, Yoon JS, Park SY, et al. Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients With Chronic Hepatitis B. Clin Gastroenterol Hepatol. 2021. PMID: 34500103. doi:10.1016/j.cgh.2021.09.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。